Study S000318

Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04775082
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 78
Start: 2021-03-04
Primary completion: 2023-08-01
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1247-8226; REGISTRY:2020-000546-34

Registered primary outcomes

Relative change in BMI (Body mass index) [From baseline (week 0) to week 56]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018425	Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. Fox CK, The New England journal of medicine	2025	Randomized trial	PMID 39258838 DOI	cites ClinicalTrials.gov:NCT04775082; registry reference RESULT:39258838
R0055747	Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. Fox, Claudia K		Randomized trial	DOI	cites ClinicalTrials.gov:NCT04775082